Quest Diagnostics Selling HemoCue Business for $300 Million

Medical company Quest Diagnostics (NYSE: DGX) announced in a press statement early Monday that it has agreed to sell its HemoCue diagnostics business, a division that makes and markets hemoglobin, glucose, and other testing products, to Radiometer Medical.

Quest expects the sale -- for $300 million along with adjustments for cash balances -- to be completed in March. The company plans to use the money to contribute to its stock-buyback program.

Quest CEO and President Steve Ruscowski elaborated on the sale in his company's release, saying, "The HemoCue divestiture, along with our sale of OralDNA in December 2012, demonstrates our commitment to refocus our business on diagnostic information services."

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.